Search Within

Larry Norton

  1. "Mark Robson"
Formats
  1. Meeting Abstract (47)
  2. Journal Article (42)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (89)
  2. Breast Medicine Service (89)
  3. Department of Medicine (89)
  4. Population Sciences Research Program (89)
  5. Solid Tumor Oncology Division (89)
  6. Survivorship Research (89)

More Groups

People
  1. Mark Robson (89)
  2. Clifford Hudis (33)
  3. Kenneth Offit (29)
  4. Chau Dang (28)
  5. Edi Brogi (23)
  6. Hannah Wen (21)

More People

Years
  1. 2024 (7)
  2. 2023 (5)
  3. 2022 (3)
  4. 2021 (2)
  5. 2020 (9)
  6. 2019 (9)

More Years

Publications
  1. Journal of Clinical Oncology (24)
  2. Breast Cancer Research and Treatment (9)
  3. Laboratory Investigation (7)
  4. Cancer Research (6)
  5. American Journal of Human Genetics (5)
  6. Clinical Cancer Research (5)

More Publications

Publishers
  1. American Society of Clinical Oncology (24)
  2. American Association for Cancer Research (14)
  3. Nature Publishing Group (14)
  4. Springer (10)
  5. Cell Press (6)
  6. Nature Research (6)

More Publishers

Results (89)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma
    Journal Article

    Hoda, R. S.; Brogi, E.; Dos Anjos, C. H.; Grabenstetter, A.; Ventura, K.; Patil, S.; Selenica, P.; Weigelt, B.; Reis-Filho, J. S.; Traina, T.; more...
    Modern Pathology (2020)

    Fulltext@MSK | Save
  • Disease free survival rate with dose dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and pertuzumab (ddACTHP) in patients with HER2-positive early stage breast cancer: A single institution experience
    Meeting Abstract

    Singh, J. C.; Patil, S.; Norton, L.; Robson, M.; Dang, C.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • The genomic landscape of breast cancer in African American women
    Meeting Abstract

    Serna-Tamayo, C.; Drago, J. Z.; Dos Anjos, C.; Herbert, J.; Pareja, F.; Modi, S.; Jhaveri, K.; Dang, C.; Solit, D. B.; Norton, L.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 guideline updates on HER2 assessment in breast cancer with equivocal HER2 immunohistochemistry results with focus on cases with HER2/CEP17 ratio <2.0 and average HER2 copy number ≥4.0 and <6.0
    Journal Article

    Hoda, R. S.; Brogi, E.; Xu, J.; Ventura, K.; Ross, D. S.; Dang, C.; Robson, M.; Norton, L.; Morrow, M.; Wen, H. Y.
    Archives of Pathology & Laboratory Medicine (2020)

    Fulltext@MSK | Save
  • Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma
    Meeting Abstract

    Wong, W.; Brogi, E.; Plitas, G.; Robson, M.; Norton, L.; Morrow, M.; Wen, H.
    Laboratory Investigation (2020)

    Fulltext@MSK | Save
  • PD-L1 expression in tumor-infiltrating lymphocytes of invasive breast carcinoma
    Meeting Abstract

    Hoda, R.; Brogi, E.; Grabenstetter, A.; Patil, S.; Selenica, P.; Weigelt, B.; Reis-Filho, J.; Traina, T.; Robson, M.; Norton, L.; more...
    Laboratory Investigation (2020)

    Fulltext@MSK | Save
  • The landscape of somatic genetic alterations in breast cancers from CHEK2 germline mutation carriers
    Journal Article

    Mandelker, D.; Kumar, R.; Pei, X.; Selenica, P.; Setton, J.; Arunachalam, S.; Ceyhan-Birsoy, O.; Brown, D. N.; Norton, L.; Robson, M. E.; more...
    JNCI Cancer Spectrum (2019)

    Fulltext@MSK | Save
  • Molecular profiling of ER plus metastatic breast cancers to reveal association of genomic alterations with acquired resistance to CDK4/6 inhibitors
    Meeting Abstract

    Razavi, P.; dos Anjos, C. H.; Brown, D. N.; Qing, L.; Ping, C.; Herbert, J.; Colon, J.; Liu, D.; Mao, M.; Norton, L.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A large retrospective analysis of CDK 4/6 inhibitor retreatment in ER+ metastatic breast cancer (MBC)
    Meeting Abstract

    dos Anjos, C. H.; Razavi, P.; Herbert, J.; Colon, J.; Gill, K.; Modi, S.; Bromberg, J.; Dang, C. T.; Liu, D.; Norton, L.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Clinicopathologic features of breast cancers with HER2/CEP17 ratio < 2, HER2 copy number ≥ 4 and < 6 signals/cell
    Meeting Abstract

    Xu, J.; Brogi, E.; Ventura, K.; Ross, D.; Dang, C.; Robson, M.; Norton, L.; Morrow, M.; Wen, H.
    Modern Pathology (2019)

    Fulltext@MSK | Save